When determining coverage policies, payers would do well to seek input from experts who can interpret the significance of oncology clinical trial data, says co-author Allan Jay Kogan, MD, medical director of Great-West Healthcare, a national MCO. Only then, he says, can decisions be made that meet the needs of all stakeholders.